Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 May;75(5):1510–1516. doi: 10.1172/JCI111855

A unique control mechanism in the regulation of insulin secretion. Secretagogue-induced somatostatin receptor recruitment.

B Draznin, J W Leitner, K E Sussman
PMCID: PMC425490  PMID: 2581996

Abstract

In this study, we have correlated the translocation of somatostatin (SRIF) receptors from the cell interior to the plasma membrane with the ability of SRIF to inhibit insulin release. Islets were perifused with glucose (30, 100, 165, 200, or 300 mg/dl) in the presence of sodium isethionate. Sodium isethionate inhibits insulin release, but not the recruitment of SRIF receptors. Thus, the recruitment of SRIF receptors to the surface membrane continued without the lysis of secretion vesicles. SRIF binding rose from 3.75 +/- 0.16 to 6.46 +/- 0.28 fmol/10 islets as glucose concentration increased. Sodium isethionate was then removed, islets perifused with low glucose (30 mg/dl), and challenged with 400 microM isobutylmethylxanthine (IBMX) with or without SRIF (5 micrograms/ml). In the islets perifused with high glucose concentration, IBMX lysed a greater number of vesicles and caused enhanced release of insulin. The greater the number of secretion vesicles marginated to the plasma membrane by glucose, the greater the response to IBMX. Colchicine (1 mM) prevented secretion vesicle migration and this potentiation effect of higher concentrations of glucose was eliminated. In experiments with IBMX and SRIF, the degree of inhibition of IBMX-induced insulin release by SRIF was proportional to the magnitude of SRIF binding to these islets. SRIF inhibited insulin release by 20 microU/100 islets initially perifused with low glucose (30 mg/dl) and by 875 microU/100 islets perifused with high glucose (300 mg/dl). The maximal effect of SRIF was observed when its binding reached a level of 5.4 fmol/10 islets. We conclude that inhibition of insulin release by SRIF is proportional to the SRIF receptor concentration, and that translocation of SRIF receptors during exocytosis plays an important role in paracrine regulation of insulin secretion by rendering the islets more sensitive to SRIF.

Full text

PDF
1510

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonner-Weir S., Orci L. New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes. 1982 Oct;31(10):883–889. doi: 10.2337/diab.31.10.883. [DOI] [PubMed] [Google Scholar]
  2. Draznin B., Leitner J. W., Sussman K. E. Kinetics of somatostatin receptor migration in isolated pancreatic islets. Diabetes. 1982 May;31(5 Pt 1):467–469. doi: 10.2337/diab.31.5.467. [DOI] [PubMed] [Google Scholar]
  3. Green I. C., Perrin D., Penman E., Yaseen A., Ray K., Howell S. L. Effect of dynorphin on insulin and somatostatin secretion, calcium uptake, and c-AMP levels in isolated rat islets of Langerhans. Diabetes. 1983 Aug;32(8):685–690. doi: 10.2337/diab.32.8.685. [DOI] [PubMed] [Google Scholar]
  4. Halter J. B., Graf R. J., Porte D., Jr Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for imparied glucose potentiation. J Clin Endocrinol Metab. 1979 Jun;48(6):946–954. doi: 10.1210/jcem-48-6-946. [DOI] [PubMed] [Google Scholar]
  5. Halter J. B., Porte D., Jr Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin. J Clin Endocrinol Metab. 1978 Jun;46(6):952–960. doi: 10.1210/jcem-46-6-952. [DOI] [PubMed] [Google Scholar]
  6. Kawai K., Ipp E., Orci L., Perrelet A., Unger R. H. Circulating somatostatin acts on the islets of Langerhans by way of a somatostatin-poor compartment. Science. 1982 Oct 29;218(4571):477–478. doi: 10.1126/science.6126931. [DOI] [PubMed] [Google Scholar]
  7. Lacy P. E., Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967 Jan;16(1):35–39. doi: 10.2337/diab.16.1.35. [DOI] [PubMed] [Google Scholar]
  8. Leitner J. W., Rifkin R. M., Maman A., Sussman K. E. The relationship between somatostatin binding and cyclic AMP-stimulated protein kinase inhibition. Metabolism. 1980 Oct;29(11):1065–1074. doi: 10.1016/0026-0495(80)90218-8. [DOI] [PubMed] [Google Scholar]
  9. Mehler P. S., Sussman A. L., Maman A., Leitner J. W., Sussman K. E. Role of insulin secretagogues in the regulation of somatostatin binding by isolated rat islets. J Clin Invest. 1980 Dec;66(6):1334–1338. doi: 10.1172/JCI109986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Orci L., Malaisse W. Hypothesis: single and chain release of insulin secretory granules is related to anionic transport at exocytotic sites. Diabetes. 1980 Nov;29(11):943–944. doi: 10.2337/diab.29.11.943. [DOI] [PubMed] [Google Scholar]
  11. Orci L., Unger R. H. Functional subdivision of islets of Langerhans and possible role of D cells. Lancet. 1975 Dec 20;2(7947):1243–1244. doi: 10.1016/s0140-6736(75)92078-4. [DOI] [PubMed] [Google Scholar]
  12. Patel Y. C., Amherdt M., Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatin binding sites on islets. Science. 1982 Sep 17;217(4565):1155–1156. doi: 10.1126/science.6126003. [DOI] [PubMed] [Google Scholar]
  13. Steinberg J. P., Leitner J. W., Draznin B., Sussman K. E. Calmodulin and cyclic AMP. Possible different sites of action of these two regulatory agents in exocytotic hormone release. Diabetes. 1984 Apr;33(4):339–345. doi: 10.2337/diab.33.4.339. [DOI] [PubMed] [Google Scholar]
  14. Sussman K. E., Draznin B., Leitner J. W., Mehler P. S. The endocrine secretion granule revisited- postulating new functions. Metabolism. 1982 Sep;31(9):959–967. doi: 10.1016/0026-0495(82)90189-5. [DOI] [PubMed] [Google Scholar]
  15. Sussman K. E., Mehler P. S., Leitner J. W., Draznin B. Role of the secretion vesicle in the transport of receptors: modulation of somatostatin binding to pancreatic islets. Endocrinology. 1982 Jul;111(1):316–323. doi: 10.1210/endo-111-1-316. [DOI] [PubMed] [Google Scholar]
  16. Sussman K. E., Pollard H. B., Leitner J. W., Nesher R., Adler J., Cerasi E. Differential control of insulin secretion and somatostatin-receptor recruitment in isolated pancreatic islets. Biochem J. 1983 Jul 15;214(1):225–230. doi: 10.1042/bj2140225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Unger R. H. The milieu interieur and the islets of Langerhans. Diabetologia. 1981;20(1):1–11. doi: 10.1007/BF00253809. [DOI] [PubMed] [Google Scholar]
  18. Zyznar E. S., Pietri A. O., Harris V., Unger R. H. Evidence for the hormonal status of somatostatin in man. Diabetes. 1981 Oct;30(10):883–886. doi: 10.2337/diab.30.10.883. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES